Table 1:

Recommendations summary^*

Category	Recommendation	Quality of evidence	Strength of recommendation
Injectable opioid agonist treatment	Injectable opioid agonist treatment should be considered for individuals with severe, treatment-refractory opioid use disorder and ongoing illicit injection opioid use.	Moderate	Conditional
Medication selection	For patients who are determined to be likely to benefit from injectable opioid agonist treatment, both diacetylmorphine and hydromorphone are acceptable treatment options.	Low	Strong
Treatment end date	Injectable opioid agonist treatment should be provided as an open-ended treatment, with decisions to transition to oral opioid agonist treatment made collaboratively with the patient.	Low	Strong

^*Protocols and other clinical guidance can be found in the full guideline in Appendix 1. The 3 key recommendations were formulated using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework and are based on the existing literature on injectable opioid agonist treatment, including 2 systematic reviews and meta-analyses.